Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours

References

• Tavassoli F P D. Pathology and Genetics: Tumours of the Breast and Female Genital Tract, No. 4. IARC, LyonFrance 2003
   Google Scholar
• Bernstein L, Deapen D, Ross R K. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993; 71: 3020–3024
   PubMed Web of Science ®Google Scholar
• Cheng S-P, Chang Y-C, Liu T-P, Lee J-J, Tzen C-Y, Liu C-L. Phyllodes tumor of the breast: the challenge persists. World J Surg 2006; 30: 1414–1421
   PubMed Web of Science ®Google Scholar
• Parker S J, Harries S A. Phyllodes tumours. Postgrad Med J 2001; 77: 428–435
   PubMed Web of Science ®Google Scholar
• Matrisian L M, Cunha G R, Mohla S. Epithelial–stromal interactions and tumor progression: meeting summary and future directions. Cancer Res 2001; 61: 3844–3846
   PubMed Web of Science ®Google Scholar
• Parmar H, Cunha G R. Epithelial–stromal interactions in the mouse and human mammary gland in vivo. Endocr Relat Cancer 2004; 11: 437–458
   PubMed Web of Science ®Google Scholar
• Fleming J M, Leibowitz B J, Kerr D E, Cohick W S. IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells. J Endocrinol 2005; 186: 165–178
   PubMed Web of Science ®Google Scholar
• Wilson C L, Sims A H, Howell A, Miller C J, Clarke R B. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006; 13: 617–628
   PubMed Web of Science ®Google Scholar
• Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol 2002; 197: 575–581
   PubMed Web of Science ®Google Scholar
• Dietrich C U, Pandis N, Rizou H, et al. Cytogenetic findings in phyllodes tumors of the breast: karyotypic complexity differentiates between malignant and benign tumors. Hum Pathol 1997; 28: 1379–1382
   PubMed Web of Science ®Google Scholar
• Wang Z C, Buraimoh A, Iglehart J D, Richardson A L. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat 2006; 97: 301–309
   PubMed Web of Science ®Google Scholar
• Sawyer E J, Hanby A M, Ellis P, et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol 2000; 156: 1093–1098
   PubMed Web of Science ®Google Scholar
• Sawhney N, Garrahan N, Douglas-Jones A G, Williams E D. Epithelial–stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer 1992; 70: 2115–2120
   PubMed Web of Science ®Google Scholar
• Brosens J J, Tullet J, Varshochi R, Lam E WF. Steroid receptor action. Best Pract Res Clin Obstet Gynaecol 2004; 18: 265–283
   PubMed Web of Science ®Google Scholar
• Cheung K L. Endocrine therapy for breast cancer: an overview. Breast 2007; 16: 327–343
   PubMed Web of Science ®Google Scholar
• Tse G MK, Lee C S, Kung F YL, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol 2002; 118: 522–526
   PubMed Web of Science ®Google Scholar
• Suo Z, Nesland J M. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features. Ultrastruct Pathol. 2000; 24: 371–381
   Google Scholar
• Umekita Y, Yoshida H. Immunohistochemical study of hormone receptor and hormone-regulated protein expression in phyllodes tumour: comparison with fibroadenoma. Virchows Arch 1998; 433: 311–314
   PubMed Web of Science ®Google Scholar
• Sapino A, Bosco M, Cassoni P, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol 2006; 19: 599–606
   PubMed Web of Science ®Google Scholar
• Shoker B S, Jarvis C, Clarke R B, et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 2000; 53: 778–783
   PubMed Web of Science ®Google Scholar
• Lien H C, Lu Y S, Cheng A L, et al. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 2006; 209: 317–327
   PubMed Web of Science ®Google Scholar
• Zandi R, Larsen A B, Andersen P, Stockhausen M-T, Poulsen H S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19: 2013–2023
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2–16
   PubMed Web of Science ®Google Scholar
• Grandis J R, Sok J C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102: 37–46
   PubMed Web of Science ®Google Scholar
• Arteaga C L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 2002; 7(Suppl 4)31–39
   PubMed Web of Science ®Google Scholar
• Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7(Suppl 4)2–8
   PubMed Web of Science ®Google Scholar
• Rocha-Lima C M, Soares H P, Raez L E, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 14: 295–304
   PubMedGoogle Scholar
• Moller P, Mechtersheimer G, Kaufmann M, et al. Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. Virchows Arch A Pathol Anat Histopathol 1989; 414: 157–164
   PubMedGoogle Scholar
• Tse G M, Lui P C, Vong J S, et al. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. Breast Cancer Res Treat 2008; Apr 29, (Epub ahead of print)
   Google Scholar
• Kersting C, Kuijper A, Schmidt H, et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 2006; 86: 54–61
   PubMed Web of Science ®Google Scholar
• Wang X, Jones T D, Zhang S, et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol 2007; 20: 175–182
   PubMed Web of Science ®Google Scholar
• Agelopoulos K, Kersting C, Korsching E, et al. Egfr amplification specific gene expression in phyllodes tumours of the breast. Cell Oncol 2007; 29: 443–451
   PubMed Web of Science ®Google Scholar
• Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61(Suppl 2)1–13
   PubMed Web of Science ®Google Scholar
• Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61(Suppl 2)67–72
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002; 63(Suppl 1)57–63
   PubMed Web of Science ®Google Scholar
• Yonemori K, Hasegawa T, Shimizu C, et al. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract 2006; 202: 705–712
   PubMed Web of Science ®Google Scholar
• Shpitz B, Bomstein Y, Sternberg A, et al. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol 2002; 79: 86–92
   PubMed Web of Science ®Google Scholar
• Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004; 36: 120–128
   PubMed Web of Science ®Google Scholar
• Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000; 11: 273–282
   PubMed Web of Science ®Google Scholar
• Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837–1851
   PubMed Web of Science ®Google Scholar
• Seidensticker M J, Behrens J. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 2000; 1495: 168–182
   PubMed Web of Science ®Google Scholar
• Yamaguchi T P. Heads or tails: Wnts and anterior-posterior patterning. Curr Biol 2001; 11: R713–R724
   PubMed Web of Science ®Google Scholar
• Sawyer E J, Hanby A M, Rowan A J, et al. The Wnt pathway, epithelial–stromal interactions, and malignant progression in phyllodes tumours. J Pathol 2002; 196: 437–444
   PubMed Web of Science ®Google Scholar
• Sawyer E J, Hanby A M, Poulsom R, et al. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J Pathol 2003; 200: 627–632
   PubMed Web of Science ®Google Scholar
• Sawyer E J, Poulsom R, Hunt F T, et al. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol 2003; 200: 59–64
   PubMed Web of Science ®Google Scholar
• Li W, Sanki A, Karim R Z, et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology. 2006; 38: 287–301
   Google Scholar
• Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med 1998; 4: 1103–1106
   PubMed Web of Science ®Google Scholar
• Michalides R. Cell cycle regulators: role in etiology, prognosis and treatment in cancer. Ann Oncol 2002; 13(Suppl 4)39
   PubMed Web of Science ®Google Scholar
• Hartwell L H, Kastan M B. Cell cycle control and cancer. Science 1994; 266: 1821–1828
   PubMed Web of Science ®Google Scholar
• Sparrow L E, Eldon M J, English D R, Heenan P J. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255–261
   PubMed Web of Science ®Google Scholar
• Hussussian C J, Struewing J P, Goldstein A M, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15–21
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995; 86: 1269–1275
   PubMed Web of Science ®Google Scholar
• Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994; 54: 6338–6339
   PubMed Web of Science ®Google Scholar
• Shapiro G I, Edwards C D, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Igaki H, Sasaki H, Tachimori Y, et al. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995; 55: 3421–3423
   PubMed Web of Science ®Google Scholar
• Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995; 55: 2756–2760
   PubMed Web of Science ®Google Scholar
• Merlo A, Herman J G, Mao L, et al. 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. [See comment]. Nat Med 1995; 1: 686–692
   PubMed Web of Science ®Google Scholar
• Jones A M, Mitter R, Springall R, et al. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 2008; 214: 533–544
   PubMed Web of Science ®Google Scholar
• Kuijper A, de Vos R AI, Lagendijk J H, van der Wall E, van Diest P J. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol 2005; 123: 690–698
   PubMed Web of Science ®Google Scholar
• Esposito N N, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs D J. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med 2006; 130: 1516–1521
   PubMed Web of Science ®Google Scholar
• Singh M, Parnes M B, Spoelstra N, Bleile M J, Robinson W A. p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. Hum Pathol 2004; 35: 1524–1530
   PubMed Web of Science ®Google Scholar
• Lee C T, Capodieci P, Osman I, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999; 5: 977–983
   PubMed Web of Science ®Google Scholar
• Pei X H, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787–2795
   PubMed Web of Science ®Google Scholar
• Lae M, Vincent-Salomon A, Savignoni A, et al. Phyllodes tumors of the breast segregate in two groups according to genetic criteria. Mod Pathol 2007; 20: 435–444
   PubMed Web of Science ®Google Scholar
• Korabiowska M, Ruschenburg I, Betke H, et al. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology 2001; 69: 274–280
   PubMed Web of Science ®Google Scholar
• Brantley M A, Jr, Harbour J W. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000; 157: 1795–1801
   PubMed Web of Science ®Google Scholar
• Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci USA 1995; 92: 11264–11268
   PubMed Web of Science ®Google Scholar
• Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 1993; 4: 897–906
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Shoji M, Jiang S X, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A–CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153: 963–972
   PubMed Web of Science ®Google Scholar
• Bukholm I R, Bukholm G, Nesland J M. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001; 93: 283–287
   PubMed Web of Science ®Google Scholar
• Lammie G A, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6: 439–444
   PubMed Web of Science ®Google Scholar
• Barbieri F, Cagnoli M, Ragni N, et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 1999; 5: 1837–1842
   PubMed Web of Science ®Google Scholar
• Kim S H, Lewis J J, Brennan M F, Woodruff J M, Dudas M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 1998; 4: 2377–2382
   PubMed Web of Science ®Google Scholar
• Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995; 146: 1161–1169
   PubMed Web of Science ®Google Scholar
• Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger H G, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998; 55: 363–369
   PubMed Web of Science ®Google Scholar
• Li J Y, Gaillard F, Moreau A, et al. Detection of translocation t(11; 14)(q13; q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999; 154: 1449–1452
   PubMed Web of Science ®Google Scholar
• de Boer C J, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995; 86: 2715–2723
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Li J Y, Facon T, et al. High incidence of translocations t(11; 14)(q13; q32) and t(4; 14)(p16; q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640–5645
   PubMed Web of Science ®Google Scholar
• Bhatt K V, Hu R, Spofford L S, Aplin A E. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 2007; 26: 1056–1066
   PubMed Web of Science ®Google Scholar
• Sauter E R, Yeo U C, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62: 3200–3206
   PubMed Web of Science ®Google Scholar
• Bhatt K V, Spofford L S, Aram G, McMullen M, Pumiglia K, Aplin A E. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005; 24: 3459–3471
   PubMed Web of Science ®Google Scholar
• Kleer C G, Giordano T J, Braun T, Oberman H A. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. Mod Pathol 2001; 14: 185–190
   PubMed Web of Science ®Google Scholar
• Tan P H, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 2005; 18: 1527–1534
   PubMed Web of Science ®Google Scholar
• Millar E K, Beretov J, Marr P, et al. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology 1999; 34: 491–496
   PubMed Web of Science ®Google Scholar
• Tse G MK, Putti T C, Kung F YL, et al. Increased p53 protein expression in malignant mammary phyllodes tumors. [Erratum appears in Mod Pathol 2002; 15: 1010.]. Mod Pathol 2002; 15: 734–740
   PubMed Web of Science ®Google Scholar
• Tse G MK, Lui P CW, Scolyer R A, et al. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol 2003; 16: 1007–1013
   PubMed Web of Science ®Google Scholar
• Dacic S, Kounelis S, Kouri E, Jones M W. Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. Breast J 2002; 8: 376–381
   PubMedGoogle Scholar
• Erhan Y, Zekioglu O, Ersoy O, et al. p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes. Breast J 2002; 8: 38–44
   PubMedGoogle Scholar
• Tomita T, Ren Y, Davis M, Tawfik O. Phyllodes tumor of borderline malignancy: a 7-year follow-up. Breast J 2003; 9: 333–334
   PubMedGoogle Scholar
• Gatalica Z, Finkelstein S, Lucio E, et al. p53 protein expression and gene mutation in phyllodes tumors of the breast. Pathol Res Pract 2001; 197: 183–187
   PubMed Web of Science ®Google Scholar
• Niezabitowski A, Lackowska B, Rys J, et al. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 2001; 65: 77–85
   PubMed Web of Science ®Google Scholar
• Koo C Y, Bay B H, Lui P CW, Tse G MK, Tan P H, Yip G WC. Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Mod Pathol 2006; 19: 1344–1350
   PubMed Web of Science ®Google Scholar
• Tse G MK, Lui P CW, Lee C S, et al. Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol 2004; 35: 1053–1057
   PubMed Web of Science ®Google Scholar
• Kuijper A, van der Groep P, van der Wall E, van Diest P J. Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res 2005; 7: R808–R818
   PubMed Web of Science ®Google Scholar
• Feakins R M, Wells C A, Young K A, Sheaff M T. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 2000; 31: 1214–1222
   PubMed Web of Science ®Google Scholar
• Tse G M, Chaiwun B, Lau K-M, et al. Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol 2007; 60: 1051–1056
   PubMed Web of Science ®Google Scholar
• Tse G MK, Wong F C, Tsang A KH, et al. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol 2005; 58: 600–604
   PubMed Web of Science ®Google Scholar
• Forrester K, Ambs S, Lupold S E, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996; 93: 2442–2447
   PubMed Web of Science ®Google Scholar
• Gallo O, Schiavone N, Papucci L, et al. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol 2003; 163: 723–732
   PubMed Web of Science ®Google Scholar
• Pukkila M J, Kellokoski J K, Virtaniemi J A, et al. Inducible nitric oxide synthase expression in pharyngeal squamous cell carcinoma: relation to p53 expression, clinicopathological data, and survival. Laryngoscope 2002; 112: 1084–1088
   PubMed Web of Science ®Google Scholar
• Tse G M, Ma T K, Chan K F, et al. Increased microvessel density in malignant and borderline mammary phyllodes tumours. Histopathology 2001; 38: 567–570
   PubMed Web of Science ®Google Scholar
• Tse G MK, Putti T C, Lui P CW, et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 2004; 17: 827–831
   PubMed Web of Science ®Google Scholar
• Carvalho S, e Silva A O, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations?. J Clin Pathol 2004; 57: 1075–1079
   PubMed Web of Science ®Google Scholar
• Chen C M, Chen C J, Chang C L, Shyu J S, Hsieh H F, Harn H J. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res 2000; 94: 84–91
   PubMed Web of Science ®Google Scholar
• Tse G MK, Tsang A KH, Putti T C, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005; 58: 185–189
   PubMed Web of Science ®Google Scholar
• Tsai W-C, Jin J-S, Yu J-C, Sheu L-F. CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system. Int J Surg Pathol 2006; 14: 127–131
   PubMed Web of Science ®Google Scholar
• Makretsov N A, Hayes M, Carter B A, Dabiri S, Gilks C B, Huntsman D G. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognoaia, estrogen receptor negativity and high grade. Mod Pathol 2007; 20: 84–89
   PubMed Web of Science ®Google Scholar
• Zamecnik M, Kinkor Z, Chlumska A. CD10+ stromal cells in fibroadenomas and phyllodes tumors of the breast. Virchows Arch 2006; 448: 871–872
   PubMed Web of Science ®Google Scholar
• Hughes T A, Brady H JM. Cross-talk between pRb/E2F and Wnt/beta-catenin pathways: E2F1 induces axin2 leading to repression of Wnt signalling and to increased cell death. Exp Cell Res 2005; 303: 32–46
   PubMed Web of Science ®Google Scholar
• Ruiz S, Segrelles C, Santos M, Lara M F, Paramio J M. Functional link between retinoblastoma family of proteins and the Wnt signaling pathway in mouse epidermis. Dev Dyn 2004; 230: 410–418
   PubMed Web of Science ®Google Scholar
• Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005; 129: 285–302
   PubMed Web of Science ®Google Scholar
• Civenni G, Holbro T, Hynes N E. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. [Erratum appears in EMBO Rep. 2003 Mar; 4: 326.]. EMBO Rep 2003; 4: 166–171
   PubMed Web of Science ®Google Scholar
• Kim S-E, Choi K-Y. EGF receptor is involved in WNT3a-mediated proliferation and motility of NIH3T3 cells via ERK pathway activation. Cell Signal 2007; 19: 1554–1564
   PubMed Web of Science ®Google Scholar
• Faivre E J, Lange C A. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007; 27: 466–480
   PubMed Web of Science ®Google Scholar
• Mulholland D J, Dedhar S, Coetzee G A, Nelson C C. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?. Endocr Rev 2005; 26: 898–915
   PubMed Web of Science ®Google Scholar
• Yang F, Li X, Sharma M, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277: 11336–11344
   PubMed Web of Science ®Google Scholar
• Takayama S, Rogatsky I, Schwarcz L E, Darimont B D. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. J Biol Chem 2006; 281: 17856–17863
   PubMed Web of Science ®Google Scholar
• Kouzmenko A P, Takeyama K-I, Ito S, et al. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem 2004; 279: 40255–40258
   PubMed Web of Science ®Google Scholar
• Das S K, Tan J, Raja S, Halder J, Paria B C, Dey S K. Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta. J Biol Chem 2000; 275: 28834–28842
   PubMed Web of Science ®Google Scholar
• Robinson G W, Hennighausen L, Johnson P F. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 2000; 14: 889–894
   PubMed Web of Science ®Google Scholar
• Tulac S, Overgaard M T, Hamilton A E, Jumbe N L, Suchanek E, Giudice L C. Dickkopf-1, an inhibitor of Wnt signaling, is regulated by progesterone in human endometrial stromal cells. J Clin Endocrinol Metab 2006; 91: 1453–1461
   PubMed Web of Science ®Google Scholar
• Rider V, Isuzugawa K, Twarog M, et al. Progesterone initiates Wnt-beta-catenin signaling but estradiol is required for nuclear activation and synchronous proliferation of rat uterine stromal cells. J Endocrinol 2006; 191: 537–548
   PubMed Web of Science ®Google Scholar
• Forget M A, Turcotte S, Beauseigle D, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007; 96: 646–653
   PubMed Web of Science ®Google Scholar
• Rao B R, Meyer J S, Fry C G. Most cystosarcoma phyllodes and fibroadenomas have progesterone receptor but lack estrogen receptor: stromal localization of progesterone receptor. Cancer 1981; 47: 2016–2021
   PubMed Web of Science ®Google Scholar